secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0000950170-25-024187
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharmaceuticals appoints Robert Azelby to board; Carl Gordon resigns
--------------------------------------------------------------------------

- Robert Azelby appointed to Board as Class I director effective Feb 20, 2025, and joins Compensation Committee.
- Carl Gordon resigned from Board effective Feb 20, 2025 after over seven years; departure not due to disagreement.
- Azelby brings 25+ years biopharma experience including CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals.
- Azelby received option to purchase 90,000 shares vesting over three years under non-employee director compensation plan.
- Company highlights TERN-701 for chronic myeloid leukemia and obesity programs approaching clinical readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/tern-20250220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-024187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer